The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients

Boshra Hasanzamani * , Maryam Hami, Vajihe Zolfaghari, Mahtab Torkamani, Mahin Ghorban Sabagh, Saiideh Ahmadi Simab

Cited by CrossRef: 18

1- Ruenroengbun N, Numthavaj P, Sapankaew T, Chaiyakittisopon K, Ingsathit A, Mckay G, Attia J, Thakkinstian A. Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta‐analysis. Transplant International. 2021;34(12):2720 [Crossref]

2- DEMİR M, MERHAMETSİZ Ö, UYAR M, SEVMİS M, AKTAS S. Outcomes of mTORi-involving minimized immunosuppression protocols in renal transplantation. 2021;4(1):71 [Crossref]

3- Howard M, Su J, Chong A. Skin Cancer Following Solid Organ Transplantation: A Review of Risk Factors and Models of Care. Am J Clin Dermatol. 2018;19(4):585 [Crossref]

4- Law J, Borrows R, McNulty D, Sharif A, Ferro C. Early renal function trajectories, cytomegalovirus serostatus and long-term graft outcomes in kidney transplant recipients. BMC Nephrol. 2021;22(1) [Crossref]

5- Savassi‐Ribas F, Gomes dos Santos de Almeida S, Baez C, Magalhães de Souza L, Wagner T, Matuck T, Monteiro de Carvalho D, Marandino Guimarães M, Varella R. Impact assessment and investigation of factors associated with herpesviruses viremia in the first year of renal transplantation. Journal of Medical Virology. 2020;92(1):107 [Crossref]

6- Ahmed H, Altyab H, Saeed S, Abdalla W, Omer A, Bellini M. Molecular Detection and Glycoprotein B (UL55) Genotyping of Cytomegalovirus among Sudanese Renal Transplant Recipients. BioMed Research International. 2022;2022:1 [Crossref]

7- Dasdelen S, Grebe S. Infections after renal transplantation. 2017;41(s1) [Crossref]

8- Higdon L, Tan J, Maltzman J. Infection, Rejection, and the Connection. 2023;107(3):584 [Crossref]

9- Stamps H, Linder K, O'Sullivan D, Serrano O, Rochon C, Ebcioglu Z, Singh J, Ye X, Tremaglio J, Sheiner P, Cheema F, Kutzler H. Evaluation of cytomegalovirus prophylaxis in low and intermediate risk kidney transplant recipients receiving lymphocyte‐depleting induction. Transplant Infectious Dis. 2021;23(4) [Crossref]

10- Callemeyn J, Senev A, Coemans M, Lerut E, Sprangers B, Kuypers D, Koenig A, Thaunat O, Emonds M, Naesens M. Missing Self–Induced Microvascular Rejection of Kidney Allografts: A Population-Based Study. JASN. 2021;32(8):2070 [Crossref]

11- Roy D, Chatterjee A, Pal A, Chatterjee R, Chakraborty N. A Decade-Long Cohort Analysis of Human Cytomegalovirus (HCMV)-Induced Early and Late Renal Rejection in Post-Transplant Patients in the Eastern Indian Population. Viruses. 2024;16(6):847 [Crossref]

12- Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P, Hauser I, Alshuth U, Kliem V. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients. 2018;102(5):876 [Crossref]

13- Dasdelen S, Grebe S. Infektionen nach Nierentransplantation. 2017;41(2):59 [Crossref]

14- Santhanakrishnan K, Yonan N, Callan P, Karimi E, Al-Aloul M, Venkateswaran R. The use of CMVIg rescue therapy in cardiothoracic transplantation: A single‐center experience over 6 years (2011‐2017). Clinical Transplantation. 2019;33(8) [Crossref]

15- Barrett‐Chan E, Wang L, Bone J, Thachil A, Vytlingam K, Blydt‐Hansen T. Optimizing the approach to monitoring allograft inflammation using serial urinary CXCL10/creatinine testing in pediatric kidney transplant recipients. Pediatric Transplantation. 2024;28(3) [Crossref]

16- El Helou G, Razonable R. Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. Expert Opinion on Drug Safety. 2019;18(11):1017 [Crossref]